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ABBREVIATIONS 
 
 
Abbreviation  Full name 
5-HT   5-hydroxytryptamine (serotonin) 
5-HTT   Serotonin transporter (SERT) 
A260   Absorbance at 260nm 
A280   Absorbance at 280nm 
AB   Aorta-banded (hypertrophied non-failing animals) 
ABHF   Aorta-banded heart failure 
AC   Adenylyl cyclase 
ACE   Angiotensin converting enzyme 
ADH   Anti diuretic hormone 
ANP   Atrial natriuretic peptide 
AR   Adrenergic receptor 
Arbp0   Acidic ribosomal phosphoprotein P0 
AT   Angiotensin 
ATP   Adenosine triphosphate 
BNP   Brain natriuretic peptide 
BSA   Bovine serum albumin 
BW   Body weight 
C   Cytidine 
cAMP   Cyclic adenosine monophosphate 
cDNA   Complementary deoxyribonucleic acid 
CHF   Congestive heart failure 
CHFR   Centre for Heart Failure Research 
CM   Cardiomyocytes 
CNS   Central nervous system 
Ct   Threshold cycle 
C-terminal  Carboxy terminal 
DAG   1,2-diacylglycerol 
dATP   Deoxy adenosine triphosphate 
dCTP   Deoxy cytidine triphosphate 
D-Glucose  Deoxy glucose 
dGTP   Deoxy guanidine triphosphate 
DNA   Deoxy ribonucleic acid 
DNase   Deoxy ribonuclease 
dNTP   Deoxy nucleotide triphosphate 
dT   Deoxy thymidine 
DTT   Dithiothreitol, Cleland's reagent 
dTTP    Deoxy thymidine triphosphate 
FRET   Förster (or Fluorescence) resonance energy transfer 
G   Guanidine 
GAPDH  Glyceraldehyde-3-phosphate-dehydrogenase 
GI   Gastrointestinal 
Gi protein  Inhibitory G protein 
GPCR   G protein-coupled receptors 
G protein  Guanine nucleotide binding protein 
Gs protein  Stimulatory G protein 
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IP3   Inositol triphosphate 
LV   Left ventricular 
LVEDP  Left ventricular end-diastolic pressure 
LVSP   Left ventricular systolic pressure 
LVW   Left ventricular weight 
M   Internal control gene-stability measure 
MHC   Myosin heavy chain 
mRNA   Messenger ribonucleic acid 
NCM   Non-cardiomyocytes 
NE   Norephinephrine 
N-terminal  Amino terminal 
NYHA   New York Heart Association 
PCR   Polymerase chain reaction 
PIP2   Phophatidylinositol-4,5-bisphosphate 
PKA   Protein kinase A 
Polr2A   Polymerase (RNA) II (DNA directed) polypeptide A 
RNA   Ribonucleic acid 
RNase   Ribonuclease 
Rpl4   Ribosomal protein L4 
Rpl32   Ribosomal protein L32 
rRNA   Ribosomal ribonucleic acid 
RT   Reverse transcriptase 
RT-PCR  Real-time polymerase chain reaction 
SEM   Standard error of the mean 
SERCA2  Sarco (endo) plasmic reticulum Ca2+ ATPase 2 
SERT   Serotonin transporter (5-HTT) 
SSIII   Super Script III 
SV   Stroke volume 
TAE   Tris-acetate EDTA 
Tbp   TATA box binding protein 
UV-light  Ultra violet light 
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1. SUMMARY 
 
Myocardial remodelling and failure are associated with alterations in gene expression 
characterised by the re-expression of a foetal gene pattern. This often involves a shift to foetal 
isoforms of contractile proteins such as e.g. MHC (myosin heavy chain). Little is known 
about whether or not serotonin receptors are part of this foetal gene program or about their 
expression in cardiomyocytes in heart failure.  
 
The aim of this study was to evaluate the expression level of 5-HT4(b), 5-HT2A and 5-HT2B 
receptors and the serotonin transporter (SERT, 5-HTT) in foetal, neonatal and adult rat hearts 
as well as in failing and Sham operated rat hearts (Sham). 
 
To determine the localisation of the 5-HT receptors regulated in hypertrophic heart failure, 5-
HT4(b), 5-HT2A and 5-HT2B expression in cardiomyocytes (CM) and non-cardiomyocytes 
(NCM) from Sham and aorta-banded animals were also studied. 
 
Foetal and neonatal rat hearts were taken out at day 3 and 1 ahead of expected birth and 1, 3 
and 5 days after birth, respectively. Hearts were also taken from adult rats at the age of 113 
days. Systolic heart failure was induced in Wistar rats by coronary artery ligation. Sham 
operated rats were run in parallel. Real-time quantitative reverse transcriptase (RT) 
polymerase chain reaction (PCR) was run using dual labelled probes. The mRNA expression 
level of 5-HT4(b), 5-HT2A, 5-HT2B and SERT was determined and normalised to the 
expression of six normalisation genes by the use of geNorm software. The results were 
compared to adult hearts or Sham. 
 
The CM and NCM fractions were isolated from Wistar rat hearts exposed to banding of the 
ascending aorta. By real-time quantitative RT-PCR the expression level of the 5-HT4(b), 5-
HT2A and 5-HT2B receptor as well as β1- and β2-adrenergic receptor (AR) of CM and NCM 
were analysed. The results were normalised to GAPDH (Glyceraldehyde-3-phosphate-
dehydrogenase) and compared to Sham. 
 
For the 5-HT4(b) receptor, the expression level in failing rat heart was modest compared to the 
foetal heart. However, it was comparable to the neonatal genotype, proposing 5-HT4(b) as a 
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reactivated foetal gene. In the aorta-banded rat heart model, the 5-HT4(b) receptor mRNA 
expression level was six times higher in both the NCM and CM of ABHF rats, compared to 
Sham. At time of birth, associated with an acute increase in wall stress, the 5-HT2A and 5-
HT2B receptor mRNA expression were increased. For the 5-HT2A receptor the expression 
level was elevated 2- and 3-fold in the NCM and CM, respectively, both in hypertrophied and 
failing heart. The 5-HT2B mRNA expression level was four times higher in NCM from heart 
failure rats but decreased by 50% in the CM heart failure group, compared to Sham. SERT 
was not regulated in foetal and neonatal hearts, or heart failure. 
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2. INTRODUCTION 
 
2.1 Heart failure 
 
Congestive heart failure (CHF) is a complex of signs and symptoms that occurs when the 
heart fails to pump an adequate cardiac output. The heart can no longer pump blood according 
to the demands of the body. Symptoms such as air hunger (dyspnoea), feeling of tiredness 
(fatigue) and oedema among others, may occur. 
 
There are several reasons for induction of heart failure; Pumping against a chronically 
elevated arterial pressure in hypertension (diastolic heart failure) and structural damage and 
impaired cardiac function due to decreased coronary blood flow (systolic heart failure) are the 
two most common ones. Most cases of heart failure can be explained by well recognised 
etiologic factors, though seemingly healthy persons may harbour risk factors for the later 
development of the disease. Cardiac risk factors include obesity, diabetes, high blood 
pressure, high cholesterol, smoking and genetics.  
 
A fundamental response to myocardial injury or altered loading conditions includes 
remodelling of the heart so that the size, shape and function of the affected chambers are 
distorted. This is accompanied by a constellation of biological changes. Together, these 
multiple alterations are very important to both the morbidity and mortality of the patients 
(Francis and Tang, 2003).  
 
Approximately 1-2% of the population is at any time affected by heart failure. It becomes 
more common with increasing age, and approximately 6% of people over the age of 64 suffer 
from heart failure or have had a failure episode. For people over the age of 74 the risk of heart 
failure is 10%. Heart failure patients are frequently in contact with the hospital and heart 
failure is a serious medical problem, both for the patient it self and the public health service 
(Gullestad and Westheim, 2004). 
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Heart failure patients are often classified according to the New York Heart Association 
(NYHA) functional classification system which relates symptoms to everyday activities and 
quality of life (Table 1). 
 
 
Table 1: The NYHA classification of congestive heart failure 
Class Patient symptoms 
Class I (Mild) No limitation of physical activity. Ordinary physical activity does not cause 
undue fatigue, palpitations or dyspnoea. 
 
Class II (Mild) Slight limitation of physical activity. Comfortable at rest, but ordinary 
physical activity results in fatigue, palpitations or dyspnoea. 
 
Class III (Moderate) Marked limitation of physical activity, Comfortable at rest, but less than 
ordinary activity causes fatigue, palpitations or dyspnoea. 
 
Class IV (Severe) Unable to carry out any physical activity without discomfort. Symptoms of 
cardiac insufficiency at rest. If any physical activity is undertaken, discomfort 
is increased. 
 
 
2.1.1 Systolic and diastolic heart failure 
Heart failure may be caused both by systolic and diastolic dysfunction. Often, both kinds will 
be present at the same time. In diastolic heart failure there are problems with ventricular 
filling, whereas in systolic failure there are problems with ventricular ejection.  
It is estimated that 20-50% of patients with heart failure have preserved systolic function or a 
normal left ventricular ejection fraction. Although such hearts contract normally, relaxation 
(diastole) will be abnormal. Compared to systolic dysfunction, diastolic heart failure has been 
studied in relatively few clinical trials. However, the mortality among patients with diastolic 
heart failure may be as high as the mortality among the systolic heart failure patients. The 
rates of hospitalisation in the two groups are equal (Jessup and Brozena, 2003). 
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Figure 1: Progression of ventricular remodelling after myocardial infarction (upper) or hypertrophic 
(lower) onset of the index event. Upper panel: An acute infarction leads to local necrosis and peripheral 
ischemia to site of infarction. Upon expansion of the affected myocardium the loss of contractile tissue is 
substantial and the ventricle wall tissue becomes thinner due to impaired cardiac function and increased end-
diastolic pressure. A sustained exposure to these conditions causes dilatation and global remodelling of the 
ventricle. Lower panel: Hypertrophy normally develops over time with an increase in ventricular wall but almost 
normal sized ventricular cavity to compensate e.g. increased pumping resistance. The compensatory concentric 
hypertrophy displaces the tissue composition (contractile vs. non-contractile tissue) which leads to ventricular 
dilatation. From Brattelid (unpublished) with permission. 
 
 
Systolic heart failure 
Systolic heart failure tends to affect men more often than women and they are typically 
between 50 and 70 years old. Myocardial damage induced by e.g. myocardial infarction is the 
main source leading to systolic dysfunction. After a myocardial infarction, the acute loss of 
myocardial cells results in abnormal loading conditions that involve not only the border zone 
of the infarction, but also remote myocardium. The remodelling continues for months after the 
initial insult, and the eventual change in the shape of the ventricle becomes deleterious to the 
overall function of the heart as a pump. The pathophysiological changes are characterised by a 
decrease in cardiac contractility, a lower stroke volume at any given end-diastolic volume. 
These abnormal loading conditions induce dilatation and change the shape of the ventricle, 
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rendering it more spherical, as well as causing hypertrophy with both a widening and 
lengthening of the individual myocytes. 
 
In dilated cardiomyopathy, the remodelling process with ventricular dilatation and 
hypertrophy occurs without the initial apparent myocardial injury observed after a myocardial 
infarction (Jessup and Brozena, 2003). The myocytes lengthen without widening, making a 
bigger chamber volume versus wall thickness.  
 
Diastolic heart failure 
Diastolic heart failure is largely a product of the aging population. The typical diastolic heart 
failure patient is often female, obese and frequently has diabetes (Jessup and Brozena, 2003). 
Diastolic heart failure occurs in patients with long standing hypertension and left ventricular 
hypertrophy. However, it may also occur in patients with hypertrophic and restrictive 
cardiomyopathy, and some of these patients may be quite young (Francis and Tang, 2003).  
 
In diastolic dysfunction the wall of the left ventricle has reduced compliance. It is abnormally 
stiff and has a reduced ability to fill adequately at normal diastolic filling pressure. The result 
is a reduced stroke volume. As mentioned earlier, one cause of diastolic heart failure is 
hypertension, and it is the chronic pumping against this elevated pressure that makes the 
ventricle stiff and less able to expand.  
 
The diagnosis of diastolic heart failure requires three conditions; 1) Presence of signs and 
symptoms of heart failure, 2) Presence of normal or slightly reduced left ventricle ejection 
fraction (>50%) and 3) Presence of increased diastolic pressure or impaired filling caused by 
delayed isovolumic relaxation or elevated stiffness (Mandinov et al., 2000).   
 
2.1.2 Pathophysiology of heart failure 
Heart failure may be caused by factors originating from the heart (intrinsic disease or 
pathology) or from external factors that place excessive demands upon the heart. Acute heart 
failure is characterised by a rapid onset of failure that can generally be reversed by therapeutic 
interventions. Acute failure may for example result from acute myocardial infarction. Chronic 
heart failure, on the other hand, results from the heart undergoing adaptive responses to a 
precipitating cause. It is this cardiac response that ultimately may lead to impaired function. 
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The failing heart tries to compensate for the lowered cardiac output, but can only cope with 
this situation for a short period of time. There will also be retention of water and salt and a 
higher peripheral resistance. However, in a prolonged perspective, these compensatory 
mechanisms actually contribute to the progression of the disease and increase the cardiac 
work load (Gullestad and Westheim, 2004). The cardiovascular system maintains arterial 
pressure and perfusion of vital organs (heart, brain and kidney) by different compensatory 
mechanisms. The most important ones are: 
 
• The Frank-Starling Mechanism. Increased venous return increases the ventricular 
filling (end-diastolic volume) and therefore preload which is the initial stretching of 
the cardiac myocytes prior to contraction. Myocyte stretching increases the sarcomere 
length which causes an increase in force generation. This mechanism enables the 
heart to eject the additional venous return, thereby increasing stroke volume (SV). 
• Myocardial hypertrophy. The mass of contractile tissue is increased, helping SV to 
increase. 
• An activation of the neurohumoral system. This includes activation of sympathetic 
nerves and the renin-angiotensin system. An increased release of vasopressin 
(antidiuretic hormone, ADH) and natriuretic peptides (atrial natriuretic peptide (ANP) 
and brain natriuretic peptide (BNP)) also occurs. 
 
Renin is released from the kidney in response to reduced renal perfusion, and circulating renin 
leads to the formation of angiotensin (AT) 1 and 2, a vasoconstrictor which in turn prompts 
adrenal aldosterone release. Aldosterone retains salt and water in the kidney and so expands 
blood volume and thereby increases preload. Vasopressin is also released and contributes to 
preserve the cardiac function by increasing vasoconstriction and water retention. It is the 
expanded blood volume that promotes the release of a natural vasodilator, ANP from atrial 
myocytes to counteract the increased preload by way of attenuation. With time, all of these 
compensatory mechanisms will increase both the ventricular afterload and preload to a point 
where stroke volume is depressed and oedemas occur. The walls will also enlarge to much 
making the blood-flow very difficult. To summarise, the pathophysiology of heart failure 
involves changes in cardiac function, neurohumoral status, systemic vascular function and 
blood volume (Figure 2). 
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Figure 2: An overview of the compensatory mechanisms involved in heart failure  
 
 
2.1.3 Medical treatment 
Heart failure is a very serious condition, and medical treatment can be very complicated. 
Some patients with heart failure will die within a short period of time, even though the 
medical treatment has been fully correct. A patient’s functionality, using modern heart failure 
treatment, will normally improve one level in the NYHA-system. The survival is also 
increased, but is limited in severe heart failure of level III or IV (Gullestad and Westheim, 
2004). 
 
With some exceptions, all heart failure conditions should be treated medically, but non- 
medical treatment such as salt and water restrictions and to stop smoking is also important to 
improve heart function. It is uncertain if there are any advantages for patients in NYHA-class 
I to use medical heart failure treatment if their ejection fraction is normal (Gullestad and 
Westheim, 2004). 
 
Increased understanding of CHF pathophysiology the last decades have caused dramatical 
changes in pharmacotherapy; from a hemodynamic model with treatment aimed at correcting 
hemodynamic defects, to a neurohumoral (often called neurohormonal) model with treatment 
aimed at preventing maladaptive, biological changes (Braunwald and Bristow, 2000). Altered 
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neurohormonal activity (norephinephrine (NE), renin, angiotensin and aldosterone) is an 
important characteristic of heart failure, and increased activity of the sympathetic and renin-
angiotensin systems are considered as important factors in the development of the disease and 
powerful predictors of shortened survival (Gullestad and Westheim, 2004). Since the 1980s, 
agents that counteract these systems, such as ACE inhibitors and β-AR-blockers, have been 
used, but still the mortality and morbidity is high for heart failure patients (Gullestad and 
Madsen, 2004). The current available neurohormonal antagonists may not antagonise all of 
the biologically active systems that become activated during heart failure, and antagonising 
alternative neurohumoral systems might be beneficial in addition to current treatment 
regimens (Qvigstad, 2004). Lately, the remodelling of the myocardium, the molecular-
biological model, has been the one given the most attention (Gullestad and Madsen, 2004). 
 
The principle of treatment is to use medicals that have documented effect on symptoms and 
prognosis, and at the same time to use the simplest regimen. Today, almost every heart failure 
patient is treated with at least an angiotensin converting enzyme (ACE) inhibitor and a β1-AR 
blocker. In addition they are often given diuretics and digitalis among others. The 
combinations depend on whether the patient has had other diseases that will affect the 
treatment and underlying causes or type of CHF.  
 
Before developing drugs, it is necessary to fully understand the pathophysiology of heart 
failure as well as the underlying mechanisms, and increased interest is turned to find the 
genetic factors involved in heart failure. Several studies have focused on polymorphisms and 
identification of gene defects that directly or indirectly are involved in the pathophysiology of 
the condition, and which may explain the inheritable part of CHF. An earlier recognition and 
correction of risk factors would provide for a more robust and favourable outcome (Francis 
and Tang, 2003). 
 
 
2.2 G protein-coupled receptors  
2.2.1 Structure and classification of G protein-coupled receptors 
G protein-coupled receptors (GPCRs) form the largest family of cell-surface receptors and 
mediate responses to a variety of ligands and stimuli, e.g. biogenic amines, nucleosides, 
lipids, amino acids and peptides, light and ions. By interacting with G proteins, GPCRs 
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mediate slow neurotransmission and affect metabolic processes by controlling the activity of 
enzymes, ion channels and vesicle transport. Approximately 50% of all active drugs are 
ligands for GPCRs. GPCRs mediate crucial cardiac effects both in the normal and failing 
heart, and altered levels of GPCRs involved in regulation of heart function may explain some 
of the differences seen in failing versus non-failing hearts.  
 
GPCRs share a common overall structure, despite the diversity of the signal molecules that 
bind to them. The structure consists of seven transmembrane α-helices, three extracellular 
loops (exoloops), three intracellular loops (cytoloops), an extracellular amino (N-) terminal 
and an intracellular carboxy (C-) terminal. Two cysteine residues in the extracellular loops are 
conserved in most GPCRs and form a disulfide link that is probably important for packing 
and stabilisation of the protein conformation (Bockaert and Pin, 1999). 
 
 
  
Figure 3: The seven classes of serotonin receptors. The serotonin receptors are divided into seven classes 
based on their sequence, pharmacological profile and signal transduction mechanism. From Brattelid 
(unpublished) with permission. 
 
 
2.2.2 Serotonin receptors 
Serotonin mediates intercellular signalling in the central nervous system (CNS) and the 
periphery through a diverse group of receptors named 5-HT1 through 5-HT7. The receptors are 
classified according to their sequence, pharmacological profile and signal transduction 
mechanisms. With exception of the 5-HT3 receptor, they all belong to the GPCR family. The 
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5-HT2 family stimulates hydrolysis of phosphatidylinositol-4,5-bisphosphate (PIP2) via Gq, 
while the 5-HT4, 5-HT6 and 5-HT7 receptors activate adenylyl cyclase (AC) trough activation 
of Gs-protein (stimulatory G protein) (Figure 4) similar to β-adrenergic receptors. 
 
Many of the serotonin receptors are encoded by a single exon, whereas others undergo 
alternative mRNA splicing of exons giving rise to receptor splice variants. Several splice 
variants have been described since the rat 5-HT4S  (“short”) and the 5-HT4L (“long”) receptors 
were cloned (Gerald et al., 1995) and later renamed 5-HT4(a) and 5-HT4(b), respectively. 
Hitherto, eight human C-terminal splice variants of the 5-HT4 receptor have been identified 
and cloned; 5-HT4(a) (Claeysen et al., 1997) (Blondel et al., 1997), 5-HT4(b) (Van den 
Wyngaert et al., 1997) (Blondel et al., 1998) (Bach et al., 2001), 5-HT4(c) and 5-HT4(d) 
(Blondel et al., 1998), 5-HT4(e) and 5-HT4(f) (Bender et al., 2000), 5-HT4(g) (Bender et al., 
2000), originally called 5-HT4(e) (Claeysen et al., 1999) (Mialet et al., 2000) and 5-HT4(n) 
(Vilaro et al., 2002). In addition, Bender et al. (2000) found an exon h which could be inserted 
in the second intracellular loop. Exon h was only observed in combination with the 5-HT4(b) 
tail and the corresponding receptor was named 5-HT4(hb). Recently Brattelid et al. (2004a) 
reported cloning, tissue distribution and pharmacological properties of a novel 5-HT4 receptor 
splice variant named 5-HT4(i). Brattelid et al. (2004a) also reported the existence of two splice 
variants encoding the human 5-HT4(g) receptor, 5-HT4(g1) and 5-HT4(g2). All 5-HT4 receptor 
splice variants cloned to date show similar pharmacological profiles.  
 
Gs protein
Serotonin
Receptor
Adenylyl
Cyclase
Synaptic membrane
ATP
cAMP
PKA 
(Protein 
Kinase A)
Phosphate
DNA
Nucleus
New gene expression (slow)
cAMP response element  
Figure 4: Intracellular signalling mechanisms initiated by activation of the Gs protein-coupled to the 5-
HT4 receptor (in nerve cells) 
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2.3 Serotonin and serotonin receptors in heart failure 
 
Serotonin is an endogenously occurring vasoactive monoamine which is predominantly 
produced in enterochromaffine cells of the gastrointestinal (GI) tract and released into the 
blood (Frishman and Grewall, 2000). Serotonin is removed from blood extracellular space 
through a high affinity transporter and is mainly stored in platelets. Circulating serotonin can 
also be taken up by sympathetic neurons and co-released with other biogenic amines 
(Kaumann, 2000) and can activate 5-HT receptors. 
 
Information about the serotonin system in CHF is limited. However, serotonin can mediate 
cardioexcitatory effects indirectly through CNS by increasing the release of norephinephrine 
from nerve terminals, and serotonin elicits positive inotropic, chronotropic and lusitropic 
effects on the heart. The receptor types that mediate these effects differ greatly between 
different species. In the rat atrium cardioexcitatory effects of serotonin are mediated via 5-
HT2A receptors (Läer et al., 1998) while in porcine and human atrium the effects are mediated 
through 5-HT4 receptors (Kaumann, 1990).  
 
The cardiac effects of serotonin have previously been thought to be restricted to the atria 
because of lack of ventricular effects. However, recent studies have demonstrated the 
presence of 5-HT4 receptor mRNA in ventricles in man (Bach et al., 2001) (Brattelid et al., 
2004b). A ventricular inotropic response to serotonin mediated by the 5-HT4 receptor was 
first demonstrated in ventricles of porcine and explanted human hearts (Brattelid et al., 
2004b). The expression of ventricular 5-HT4 receptor mRNA is enhanced 4-fold in heart 
failure and associated, in a patient-dependent manner, with serotonin-stimulated increases in 
contractility, hastening of relaxation and arrhythmias, mediated through 5-HT4 receptors 
(Brattelid et al., 2004b). A 5-HT4 receptor-mediated inotropic response to serotonin was also 
observed in failing and infarcted rat hearts. The response was not present in normal 
ventricular myocardium (Qvigstad et al., 2005a). The 5-HT4 receptor-mediated inotropic 
response to serotonin in infarcted and failing hearts is associated with an increase in the 5-HT4 
receptor mRNA level.  
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The apparently similar inotropic role of the 5-HT4 receptor in failing human and rat ventricle 
suggests that CHF in rat is a good model for characterisation of the 5-HT4 receptor in the 
failing human heart. 
 
In acute heart failure, a situation associated with increased wall stress, an inotropic response 
to serotonin is also observed. It is mediated through a cAMP-independent mechanism via Gq-
coupled 5-HT2A receptors and a cAMP-dependent mechanism via Gs-coupled 5-HT4 receptors 
analogous to what is seen for adrenoceptors (α1 and β) (Qvigstad et al., 2005b). 
 
Concerning the 5-HT2B receptor, Nebigil et al. (2001) have demonstrated a hypertrophic role 
of the 5-HT2B receptor in the developing mouse heart. Transgenic mice overexpressing the 5-
HT2B receptor display a cardiac hypertrophic phenotype, whereas ablation of the 5-HT2B 
receptor in mice leads to dilated cardiomyopathy. 
 
The 5-HT transporter (5-HTT, SERT) is present with high density in foetal cardiomyocytes 
mediating an uptake of 5-HT into cells (Sari and Zhou, 2003). Their findings demonstrate a 
role of SERT by regulating 5-HT in development of foetal heart cells and its implication in 
the proliferation.  
 
 
2.4 The foetal gene program 
 
Myocardial remodelling and failure are associated with alterations in gene expression 
characterised by the expression of a foetal gene pattern (Maytin and Colucci, 2002). This 
often involves a shift to foetal isoforms of contractile proteins such as myosin heavy chain 
(MHC) and alterations in calcium handling proteins to levels that are characteristic of foetal 
myocardium (decreased SERCA2, increased sodium/calcium exchanger). The natriuretic 
peptides, ANP and BNP are normally expressed in foetal myocardium. They are also 
markedly induced in remodelling myocardium and are both detectable in the blood where they 
may be used as an indirect marker for myocardial overload (Maytin and Colucci, 2002). The 
profile of gene expression in the foetal and failing human heart, however, is largely unknown.  
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In a study by Razeghi et al. (2001) where they focused on the genes of energy substrate 
metabolism, they found that the failing adult heart reverts back to a foetal metabolic gene 
profile by down-regulation of adult gene transcripts rather than by up-regulating foetal genes. 
The reactivation of the foetal gene program could reflect an adaptive response towards an 
energy sparing metabolic profile.  
 
Little is known about whether or not 5-HT receptors such as the 5-HT4 receptor increased in 
heart failure, could be a part of a foetal gene program reactivated in heart failure. 
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2.5 Purpose and aims 
 
The significant increase in ventricular 5-HT4 receptor mRNA and 5-HT4-mediated inotropic 
response in CHF may play an important role in the cardiac pathophysiology of heart failure 
(Brattelid et al., 2004b) (Qvigstad et al., 2005a). A hallmark of heart failure is the transition in 
gene expression towards a foetal genotype which correlates with loss of cardiac functions. At 
present there is no evidence of a role of the 5-HT4 receptor in the foetal heart. 
 
The increased 5-HT4 mediated inotropic effect in company with an increased 5-HT4 mRNA 
level in failing left ventricle (Qvigstad et al., 2005a) implies a co-localisation of these 
responses to the cardiomyocytes. Due to lack of antibodies with high specificity and 
sensitivity, localisation of the 5-HT4 receptor in the failing heart has not been possible. 
 
The aim of this study was therefore to determine if the 5-HT4 receptor may be a part of the 
foetal gene program, and whether or not 5-HT4 receptor mRNA is found in the cardiomyocyte 
and/or non-cardiomyocyte fractions of failing hearts. 
 
Recent studies in our lab have demonstrated that 5-HT2A is involved in acute CHF and 
longstanding hypertrophic heart failure (Qvigstad et al., 2005b) (Brattelid et al., 2005a). 
Nebigil et al. (2003) have demonstrated that the 5-HT2B receptor plays a significant role in 
heart development and hypertrophy. It was therefore important to also screen whether the 5-
HT2A and the 5-HT2B receptors are involved in the foetal gene program as well as their 
appearance in cardiomyocytes and the non-cardiomyocytes in hypertrophic heart failure. Due 
to the apparently central role in foetal heart development, the expression level of the serotonin 
transporter, SERT was also included in the foetal gene program study. 
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3. MATERIALS AND METHODS 
 
3.1 The rat models 
 
Foetal and neonatal rats 
Female Wistar rats were kept in separate cages and housed with a male Wistar rat for 48 hours 
to ensure a successful mating. At day 3 and 1 ahead of expected birth, the mother was 
euthanized under anaesthesia (68% N2O, 29% O2 and 2-3% isofluran (Abbot Park, Illinois, 
USA)), and the foetal rats were taken out of the uterus. All the foetal and neonatal rats in each 
litter were killed by decapitation and hearts were removed and stored in RNAlater (Ambion). 
 
Normal adult rats 
Male Wistar rats 113 days of age (age matched with the 6 weeks MI rats described below) 
were euthanized under anaesthesia (68% N2O, 29% O2 and 2-3% isofluran), hearts were 
removed and immediately stored in RNAlater. 
 
The myocardial infarction (MI) heart failure model  
Animals were cared for according to the Norwegian Animal Welfare Act, and two rats 
(Møllegaard Breeding and Research Centre, Skensved, Denmark) were kept in each cage and 
housed in a temperature regulated room on a 12:12-h day/night cycle. The animals were given 
access to food and water ad libitum. An extensive infarction was induced by proximal ligation 
of the left coronary artery in 320g male Wistar rats under anaesthesia (68% N2O, 29% O2 and 
2-3% isofluran).  
 
The rats were anaesthetised and ventilated as described above, six days after infarction, and 
they were characterised for left ventricular end-diastolic pressure (LVEDP) measurements. 
CHF rats with a LVEDP > 15mmHg and a significantly increased heart and lung weight were 
included in the study (Sjaastad et al., 2000). The CHF classifications were also confirmed 
with quantitative RT-PCR to screen for increased expression of ANP mRNA. 
 
Sham operated rats (Sham) were run in parallel. They underwent the same surgical procedure, 
but the coronary artery was not ligated. 
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Aortic banding model 
Animals were cared for according to the Norwegian Animal Welfare Act, and two animals 
were kept in each cage and housed in a temperature-regulated room on 12:12-h day/night 
cycle. The animals were given access to food and water ad libitum.  
 
Male Wistar rats (Møllegård Breeding and Research Center, Skensved, Denmark) weighing 
200g were anaesthetised with 68% N2O, 29% O2 and 2-3% isofluran and ventilated on a 
respirator (Zoovent, Triumph Technical Services, Milton Keynes, UK). The ascending aorta 
was dissected free through a hemithoracotomy on the right side. A stenosis of the aorta 
ascendens was induced by a ligation (3-0 silk) which included both the aorta and a steel wire 
(0.9 mm). Immediately after the ligation the steel wire was removed. This resulted in a ~0.9 
mm aortic diameter. Subsequently the chest was closed and the animals were given analgesic 
drugs. The Sham operated rats were subjected to the same surgical procedure without banding 
of the ascending aorta.  
 
After six weeks the rats were again anaesthetised and ventilated on the respirator. 
Echocardiography was performed and the heart excised into saline, weighed and mounted on 
a modified Langendorf setup. After removal of the left ventricle (LV) posterior papillary 
muscle, the right ventricle (RV) and LV weights were measured. The aorta-banded (AB) 
animals were grouped into failing (ABHF) and non-failing animals (AB). As criteria, the 
ABHF animals had both lung weight (>2.0g) and left atrial diameter (>5.0mm) increased 
compared to Sham and AB groups. The banded animals that did not fulfil these criteria were 
divided into 3 groups (AB1, AB2, AB3) based on the degree of LV hypertrophy (LV weight 
to body weight (BW) ratio). 
 
M-mode, two-dimensional and Doppler echocardiography was performed with a VIVID 7 
echocardiograph (GE Vingmed Ultrasound, Horten, Norway (GE)) using a M12L 12MHz 
linear array transducer (GE) and analyzed essentially as described by Sjaastad (2000). 
 
3.1.1 Tissue sampling 
All the cardiac tissue isolated was collected and stored in RNAlater according to the 
manufactures recommendations until further processing. RNAlater is an aqueous, non-toxic 
tissue storage reagent that rapidly permeates tissue to stabilise and protect cellular RNA in 
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situ in unfrozen specimens. Tissue conserved in RNAlater can be stored at -20ºC long-term. 
At 25ºC, RNAlater preserves RNA in tissue for up to one week. 
 
Isolation of ventricles from foetal and neonatal hearts 
Foetal and neonatal ventricles were dissected free from atria under magnifying glass. 
Ventricles from each litter were pooled and stored in an excess of RNAlater. 
 
Isolation of 113-day-old rat hearts 
Hearts of 113-day-old rats were dissected into right and left ventricle and septum and stored 
in RNAlater. Only septum was processed further. 
 
Isolation of MI rat heart tissue 
Rats, still under anaesthesia, were euthanized, the heart was removed and viable tissue from 
the left ventricle (mostly septum) was isolated and immediately submerged in RNAlater for 
storage until further processing. To avoid sampling errors, tissues from left ventricle were 
collected from the same areas in Sham and CHF rats.  
 
Isolation of cardiomyocytes from banding rat hearts 
Ventricular cardiomyocytes were isolated from hearts pre-treated with heparin (170IE in 
0.2ml, Leo, Ballerup, Denmark) before excision and perfusion at 37ºC with a preoxygenated 
solution containing (mM) NaCl 130, Hepes 25, D-Glucose 22, KCl 5.4, MgCl2 0.5, NaH2PO4 
0.4 and insulin 0.01g/ml, pH 7.4. After 1-2 min, collagenase Type II (201U/ml, Worthington) 
and 0.1 mM Ca2+ was added to the solution, and the heart was perfused until the aortic valve 
ruptured. The LV free wall and the septum was minced and gently triturated at 37°C in the 
collagenase solution with 1g/l bovine serum albumin (BSA). The cell suspension was filtered 
(200µm nylon mesh) and sedimented. The supernatant was kept for non-cardiomyocyte 
fraction, and the pellet was resuspended in solution I containing 0.1mM Ca2+ and 1g/l BSA. 
After sedimentation, the pellet (59% cardiomyocytes) was frozen on liquid N2. The 
supernatant from both sedimentations was centrifuged at 120g, and the pellet (86% non-
cardiomyocytes) was frozen on liquid N2. 
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3.2 Isolation of RNA 
3.2.1 Homogenisation 
RNAlater conserved tissues (100mg/1.5ml Trizol) were washed in 0.9% NaCl to remove salt 
residuals and homogenised in 2ml tubes (Sarstedt) with Trizol (Invitrogen) and a ceramic 
particle to grind the tissue, using a shaking machine (Retsch MM301, Retsch) at 30.0 Hz for 
20 minutes. Trizol reagent maintains the integrity of the RNA while disrupting cells and 
dissolving cell components pre-conserved in RNA later. Following homogenisation insoluble 
material was removed by centrifugation at 12000 x g for 10 minutes at 2-8ºC. The resulting 
pellet contains high molecular weight DNA, extracellular membranes and polysaccharides. 
(See protocol description 8.2.1) 
 
3.2.2 Phase separation, RNA precipitation and RNA wash 
A major goal of nucleic acid isolation is the removal of proteins. Separation can be 
accomplished due to differences in chemical properties. The highly charged phosphate 
backbone makes the nucleic acids rather hydrophilic while proteins are more hydrophobic. 
Addition of chloroform followed by centrifugation in eppendorf tubes loaded with Phase 
Lock Gel (Heavy 2ml, Eppendorf), isolates RNA in the colourless upper aqueous phase. The 
proteins will remain in the lower chloroform phase, whereas genomic DNA is found in the 
organic and aqueous interphase. The RNA was precipitated by mixing the aqueous phase with 
isopropanol and collected by centrifugation at 12000 x g. The RNA pellets were washed with 
ethanol and dissolved in RNase-free water (Ambion). RNaseOut (Invitrogen) (1µl/20µl 
solution) was added to inhibit RNase activity. The samples were stored at -70ºC. (See 
protocol description 8.2.1) 
 
Concerning all procedures: 
To avoid introducing exogenous RNases to the samples, all reagents used were RNase-free, 
and all the equipment was decontaminated with RNase-OFF (AppliChem) routinely. Gloves 
were worn all the time and changed frequently.  
 
3.2.3 Determination of RNA purity, concentration and quality 
The RNA quality was assessed by spectrophotometry and gel electrophoresis. The 
concentration of RNA in the samples was determined spectrophotometrically by measuring 
the absorbance at 260nm (A260). The ratio between the absorbance at 260nm and 280nm 
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(A280) gives an estimate of the RNA purity concerning proteins. (See protocol description 
8.2.2) 
 
To verify RNA quality, the samples were fixed in formamide and subjected to agarose gel 
electrophoresis to separate the 28S and 18S rRNA fragments. RNA is a negatively charged 
molecule, at least at neutral pH, and in an electrical field it will move towards the positive 
pole. The migration of RNA is dependent on factors such as size, conformation, agarose 
concentration, buffer concentration and the voltage used. RNA was stained with ethidium 
bromide and the RNA integrity assessed by visualisation under ultra violet (UV) light. Two 
distinct bands, one each for 28S and 18S, should be visible when the samples are of high 
quality and RNA has not been degraded. (See protocol description 8.2.3) 
 
 
3.3 DNase treatment procedure 
3.3.1 DNase treatment 
Total RNA isolated by the Trizol-method is not absolutely free from DNA. To remove DNA 
residuals all samples were DNase treated. The DNase (RQ1 RNase-free DNase (1U/µl), 
Promega) digests every strand of DNA present, both single and double stranded in an Mg2+ 
buffer (RQ1 RNase-free DNase 10X Reaction Buffer). By removing the DNA a more 
accurate gene expression analysis is achieved. To terminate the reaction a DNase Stop 
solution (RQ1 DNase Stop Solution, Promega) was added. Incubation at 65ºC for 10 minutes 
inactivates the DNase enzyme. (See protocol description 8.2.4) 
 
3.3.2 Precipitation and washing of RNA after DNase treatment 
The DNase treated RNA samples were precipitated by addition of ammonium acetate, 
Glycoblue (glycogen coupled to a blue stain, Ambion) and absolute ethanol. Glycogen acts as 
a carrier to increase the precipitation efficiency from dilute RNA solutions. The blue stain 
makes the pellets blue and therefore easier to see. Ammonium acetate also helps precipitating 
the RNA. The precipitate was washed in ethanol and dissolved in RNase-free water. 
RNaseOut was added before storage at -70ºC. (See protocol description 8.2.5) 
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3.3.3 The use of NanoDrop for RNA purity- and concentration-determination  
The NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies) is a full-spectrum 
(220-750nm) spectrophotometer that measures samples down to 1µl with high accuracy and 
reproducibility. The small sample drop is positioned on the instrument by surface tension 
alone. 
 
Diluted (1:10) samples of 2µl were used, and whilst running, they were kept on ice. All 
samples were run twice and RNase-free water was used as a blank. (See protocol description 
8.2.6) 
 
3.3.4 The use of Bioanalyzer for quality verification 
The Agilent 2100 Bioanalyzer (Agilent Technologies) is a microfluidisc-based platform for 
the analysis of DNA, RNA, proteins and cells by capillary electrophoresis. It is an alternative 
to gel electrophoresis techniques; delivering fast, reproducible, high quality digital data. An 
electropherogram (chromatogram) showing the 28S and 18S peaks, is generated for each 
RNA sample included in the study, and the system automatically calculates the ratio of the 
ribosomal bands (28S/18S). A maximum of 12 RNA samples are loaded to a chip preloaded 
with gel-dye mix, a marker (RNA 6000 Nano Marker, Agilent Technologies) and a ladder 
(RNA 6000 Ladder, Ambion). The samples were diluted with RNase-free water according to 
the total RNA qualitative detection area (5-500ng/µl) and kept on ice during the preparation 
procedure. (See protocol description 8.2.7) 
  
3.3.5 Making a standard curve 
To make a standard curve for the PCR, the same amount (5µg) of total RNA from six 
different samples were pooled together in one tube. Based on spectrophotometric 
quantification, amounts of 10, 7.5, 5, 2.5 and 0.5µg template were pipetted into separate 
tubes. First strand cDNA synthesis was carried out as described below. 
 
 
3.4 First strand cDNA synthesis 
 
Single stranded mRNA is too unstable to serve as a template for PCR, and mRNA is therefore 
transcribed into the much more stable cDNA (complementary DNA). This is all accomplished 
29 
by the use of the reverse transcriptase SuperScript III (SSIII, Invitrogen). 5.0µg (7.5µg for the 
cardiomyocytes and non-cardiomyocytes) RNA was mixed together with oligo dT primers, a 
dNTP Mix (same amount of dATP, dGTP, dCTP and dTTP, all Invitrogen) and RNase-free 
water to a volume of 26µl. Heating to 65ºC allows the primers to anneal. SSIII, RNaseOut, 
First-Strand Buffer (Invitrogen) and DTT (Invitrogen) were added to a total volume of 40µl. 
To synthesise the cDNA a special temperature-program was used: 
 
1. 25ºC for 5 minutes 
2. 50ºC for 60 minutes 
3. 70ºC for 15 minutes (inactivation of the reaction) 
 
Reactions without reverse transcriptase (-RT reactions) were run in parallel. This was carried 
out to control for genomic DNA contamination. In these samples SSIII and RNaseOut was 
replaced by DNase-free water. (See protocol description 8.2.8) 
 
 
3.5 Primer and probe design 
 
The design of good primers and probes is very important to get an effective amplification of 
the target gene and reliable signals that are not due to primer dimers, primer-probe dimers or 
replication of other genes due to unspecific binding. While designing primers and probes 
there are several guidelines that should be followed (See protocol description 8.2.9). In the 
transcription process from genomic DNA to mRNA the introns are removed and the exons 
coupled together, and if it is possible, the primers should be designed over an exon-exon 
junction. This is to avoid replication of genomic DNA. Different software can be used to 
design primers and probes with the correct melting temperature and to check for secondary 
structures, primer dimers and primer-probe binding. With exceptions of some primers and 
probes for normalisation, primers and probes used in this study were designed by Primer 
Express software (Version 2.0.0, Applied Biosystems) (See protocol description 8.2.9). 
Almost all primers and probes were obtained from Invitrogen and Eurogentec, respectively, 
but the primers and probes for Rpl4, Rpl32 and Arbp0 were obtained as mixes from Applied 
Biosystems. (See Table 2 for further information) 
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3.6 Polymerase chain reaction (PCR) 
3.6.1 Basic principles 
PCR is an extremely sensitive method to amplify a selected DNA sequence in vitro. The 
method requires two primers, a polymerase enzyme and a dNTP mix. A temperature program 
is started and the DNA sample is first heated to separate the two strands. In a second step the 
temperature is lowered just below the melting point of the primers to allow them to hybridise 
to their DNA sequence. Finally, the temperature is increased to the optimum of the 
polymerase, usually 68-72ºC, to replicate the DNA. In practice, 20-30 cycles of reaction is 
required for effective DNA amplification. Each cycle doubles the amount of DNA and takes 
about 5 minutes in an automated temperature cycler. 
 
The polymerase used is a Taq DNA polymerase. This is a thermostable enzyme isolated from 
the thermophilic bacterium Thermus aquaticus. This enzyme survives prolonged exposure to 
temperatures as high as 95ºC. Because of this it will still be active after the denaturation steps 
in the PCR procedure. Normal DNA polymerase would have denatured together with the 
DNA at temperatures this high. 
 
3.6.2 Real-time quantitative RT-PCR 
Real-time quantitative RT-PCR was accomplished for all the selected genes including the 
genes used for normalisation. Using a probe, in situ quantification of reaction product is 
possible. The TaqMan probe is a short singlestranded oligonucleotide sequence that is 
complementary to one of the strands of the amplicon. At the 5´-end of the probe there is a 
fused reporter sending out a fluorescent signal.  At the other end there is a quencher. Both the 
reporter and the quencher are fluorophores. When the probe is intact and in solution or bound 
to its corresponding DNA sequence, the proximity of the quencher will reduce the fluorescent 
signal sent out by the reporter. This is all due to FRET (Förster (or Fluorescence) resonance 
energy transfer) where the reporter transfers its energy to the quencher which releases the 
energy as light of a higher wavelength. The DNA polymerase used for quantitative RT-PCR 
displays a 5´-3´ nuclease activity. This means that it can hydrolyse an oligonucleotide bound 
to its target sequence. Based on this the reporter is separated from the quencher during the 
synthesising process. When the reporter separates from the quencher, as when the polymerase 
replicates the template and hydrolyses the probe, fluorescent signals will be sent out. FRET 
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will no longer occur when the reporter and quencher are separated. This is detected by the 
real-time quantitative RT-PCR machine as an increase in emitted light intensity. 
 
 
 
 
 
 
Figure 5: Quantification of mRNA by probe based real-
time quantitative RT-PCR. Increasing amount of 
fluorescence signal is emitted as the sequence is amplified 
and the reporter and quencher dyes are separated. From 
Brattelid (unpublished) with permission. 
 
 
When Taq Man and other dual-labelled probes are used, a 2-step cycling program is run. In 
the first step the temperature is raised to 94ºC to denature the polymerase. In a second step of 
60ºC, the annealing and extension are all done at once. In addition an initial activation of the 
polymerase is required. This is accomplished by heating to 95ºC for 15 minutes.  
 
The real-time quantitative RT-PCR assays (20µl) were run in a 384-well temperature block 
operated by an ABI Prism 7900HT Sequence Detection System (Applied Biosystems). (See 
protocol description 8.2.10) 
 
The Ct (cycle of threshold) value is defined as the cycle number at which the fluorescence is 
higher than the baseline fluorescence. The higher the starting copy number of the genomic 
material target, the sooner this is reached. 
 
 
3.7 Calculations 
3.7.1 Analysis of quantitative RT-PCR data 
An amplification plot was generated from every sample. This was carried out using Sequence 
Detector Software (SDS version 2.2, Applied Biosystems). The amplification plots show an 
increase in fluorescence from the reporter with each PCR cycle. Ct values from each 
amplification cycle were automatically calculated. The Ct value represents the number of PCR 
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cycles where fluorescence is first detected above the baseline. The Ct value is obtained in the 
linear phase of PCR where there are no rate-limiting components. The Ct values were then 
exported into Excel (Microsoft) for further calculations.  
 
Standard curves for each primer/probe set were made by plotting Ct values versus log initial 
amount of RNA for the different standard dilutions. This plot gives a straight line (Equation 
1) and the slope describes the efficiency of the PCR. If the PCR amplification is optimal, the 
slope will be -3.3, as 3.3 is the number of cycles that are required to generate a 10 fold 
increase in product amount.  
 
Ct = a (log Q) + b       (1) 
 
Ct -cycle of threshold, a is the slope, Q is the initial amount of RNA and b is the intercept on 
the y-axis. 
 
Equation 1 can easily be rearranged to; 
 
a
bCQ t −=log        (2) 
 
Using this equation with the slope a and intercept b calculated from the standard curve and 
the obtained Ct values for the different samples, the initial amount of target RNA can be 
calculated. 
 
Normalisation genes 
To normalise for differences in the amount of template added, for sample to sample variations 
in RT-PCR efficiency and for errors in sample quantifications the expression level of each 
gene analysed are normalised to a so called housekeeping gene. GAPDH (Glyceraldehyde-3-
phosphate-dehydrogenase) is probably the most frequently used normalisation gene for 
quantitative RT-PCR analysis, but actually not very suitable for comparison of CHF vs. Sham 
hearts (Brattelid et al., 2005b). Due to lack of RNA and knowledge of normalisation genes to 
use in quantitative RT-PCR, GAPDH only was used for normalisation in the cardiomyocyte 
and non-cardiomyocyte part of this thesis. 
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Concerning the foetal gene program study, five normalisation factors additionally to GAPDH 
were included; Tbp (TATA box binding protein), Polr2A (Polymerase (RNA) II (DNA 
directed) polypeptide A), Rpl4 (Ribosomal protein L4), Rpl32 (Ribosomal protein L32) and 
Arbp0 (Acidic ribosomal phosphoprotein P0) (Brattelid et al., 2005b). The normalisation 
calculations were carried through by the method of Vandesompele et al. (2002) using the 
Excel based program geNorm. Based on all the normalisation genes, geNorm calculates a 
normalisation factor for each sample. 
Each sample was run in triplicates, and the mean values of the triplicates were used to 
calculate initial amount of RNA for each sample. To normalise, this value was then multiplied 
by its corresponding normalisation factor obtained by geNorm. 
 
Finally, values of initial amount of RNA of the target gene relative to the normalisation genes 
were transferred into GraphPad Prism4 Software (Prism) for statistical comparison and 
graphical presentation. All data were expressed as mean ± SEM from n litters or animals. p < 
0.05 was considered statistically significant (nonparametric Mann-Whitney). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Schematic overview of the methodological steps 
and problems involved in quantitative RT-PCR. Tissue is 
sampled immediately after sacrifice of animal and stored 
until isolation of total RNA. Sampling procedure and 
temperature exposure is essential to reduce tissue 
contamination and degradation of the RNA. The method 
chosen for RNA isolation is usually tissue dependent. Several 
strategies are available for synthesis of cDNA. Priming 
strategy, oligo dTs, random hexamers or gene specific 
primers, and activity and optimal temperature of the RT-
enzyme is of importance for the cDNA synthesis and quality 
of the cDNA. Due to RNase contamination, the RNA is most 
vulnerable when isolated, but significantly more stable when 
transcribed into cDNA. The efficiency of the quantitative RT-
PCR is dependent on primers and probe specificity and 
number of copies of gene of interest in sample. Likewise the 
processing of the results and the normalisation strategy might 
play an important role for the outcome of quantitative RT-
PCR. From Brattelid (unpublished) with permission. 
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4. RESULTS 
 
To address whether serotonin receptors and the serotonin transporter (SERT, 5-HTT) are 
involved in the foetal gene program reactivated in heart failure, the level of mRNA encoding 
5-HT4(b), 5-HT2A, 5-HT2B and SERT were analysed by real-time quantitative RT-PCR in 
foetal, neonatal and adult as well as Sham and CHF (congestive heart failure) operated rat 
hearts (CHF). To accomplish this extensive study, PCR was run in 384-well plates (384-Well 
Clear Optical Reaction Plate, Applied Biosystems) on cDNA obtained from the same cDNA 
synthesis. 
 
To correct for sample variations, all the real-time quantitative RT-PCR data from the genes 
examined were multiplied by a normalisation factor (based on the expression of six 
normalisation genes (Table 3)) generated for each sample by the Excel-based program 
geNorm (Vandesompele et al., 2002). According to Brattelid et al. (2005b) the five 
housekeeping genes Rpl4, Arbp0, Rpl32, Tbp and Polr2A are all fairly stable normalisation 
genes in heart. Additionally GAPDH was also used for normalisation. The foetal gene 
expression levels were compared to the adult (113-day-old) whereas CHF was compared to 
the Sham group. Both the adult and the Sham group were assigned the value of 1 for 
simplifying the comparison of groups. 
 
geNorm automatically calculates the internal control gene-stability measure M (defined as the 
average pairwise variation of a particular gene with all other control genes) for all the control 
genes included. Genes with the most identical and stable M values have the most stable 
expression. All normalisation genes should have M values under approximately 1.5 to be 
stable enough and not to be excluded from incorporation into the calculated normalisation 
factor value. All the normalisation genes included in the foetal gene program study had M 
values under this value (Table 3).  
 
 
Table 3: Achieved M values in geNorm 
GAPDH Rpl4 Arbp0 Rpl32 Tbp Polr2A
0.664 0.327 0.336 0.414 0.399 0.438 
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4.1 Animal characteristics 
4.1.1 The MI heart failure model 
The post-infarction heart failure model induced by coronary artery ligation induced 
hemodynamic changes characteristic for dilated cardiomyopathy with elevated LVEDP and 
decreased left ventricular systolic pressure (LVSP). These hemodynamic changes resemble 
those observed previously in this model (Sjaastad et al., 2003). Tachypnoea, pleural effusion 
and pulmonary congestion were present in the CHF animals. Animal characteristics are 
summarised in Table 3. All the Sham and CHF rats included in the foetal gene program study 
were taken from these groups of animals, with n = 5 and n = 6 for Sham and CHF, 
respectively. 
 
 
Table 4: Animal characteristics. Animal characteristics are given as mean values ± SEM. LVEDP, left 
ventricular end-diastolic pressure; LVSP, left ventricular systolic pressure; RV, right ventricle. *CHF vs. Sham p 
< 0.05; ***CHF vs. Sham p < 0.001.   
 Sham 
(n = 9) 
CHF 
(n = 18) 
Body weight, g 380 ± 10 374 ± 10 
Heart weight, g 1.42 ± 0.04 2.51 ± 0.10*** 
Heart weight/ body weight, g/kg 3.74 ± 0.14 6.71 ± 0.32*** 
RV weight, g 199 ± 15 488 ± 26*** 
Lung weight, g 1.41 ± 0.04 4.33 ± 0.20*** 
LVEDP, mmHg 4.0 ± 1.3 23.0 ± 1.6*** 
LVSP, mmHg 101 ± 5 88 ± 4* 
 
 
4.1.2 Aorta-banded animals 
Aortic banding induced a significant increase in left ventricle weight (LVW) in AB 1-3 
(hypertrophic group) and ABHF (heart failure group) compared to Sham. Lung weight was 
increased in ABHF compared to AB 1-3. 
 
The flow velocity also increased to >6m/s over the aortic stenosis subsequently increasing the 
LV wall stress, partially compensated by myocardial hypertrophy. Exceeding the 
compensation limits, the hypertrophic heart will no longer be able to adjust for the increase in 
afterload, resulting in left ventricular dilatation and CHF. 
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Figure 7: Representative 2-D images of the left ventricle (LV) in end diastole. In AB2 and ABHF the LV 
wall thickness is increased compared to Sham. In ABHF the LV is dilated compared to AB2. In ABHF the left 
atrial (LA) diameter is larger than in Sham and AB2. LA -left atrium; IVS -inter ventricular septum; LV -left 
ventricle lumen; PW -posterior left ventricular wall. Modified after Brattelid et al. (2005a). 
 
 
 
 
 
 
 
 
 
Figure 8: M-Mode images of the LV. The AB2 group develops concentric left ventricle (LV) hypertrophy, and 
the LV dilates in the ABHF group. IVS -inter ventricular septum; LV -left ventricle lumen; PW -posterial left 
ventricular wall. Modified after Brattelid et al. (2005a). 
 
 
 
 
 
 
 
 
 
Figure 9: Doppler signals. The deceleration velocity of the mitral valve Doppler signal is increased in ABHF 
compared to Sham and AB2. Modified after Brattelid et al. (2005a). 
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4.2 The foetal gene program 
4.2.1 The expression of ANP 
The level of ANP is known to increase significantly in CHF hearts, and quantification of 
mRNA encoding ANP was performed to confirm the presence of CHF in the heart failure 
group.   
 
The level of ANP mRNA was significantly increased in the CHF group when normalised 
against the six normalisation genes. Compared to adult hearts, ANP mRNA expression was 
elevated 2-10-fold in foetal and neonatal hearts and about 110-fold in CHF.  
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Figure 10: The mRNA expression of ANP in foetal, neonatal, adult and failing rat hearts quantified by the 
use of real-time quantitative RT-PCR. The foetal and neonatal groups (-3 days to 5 days) are compared to the 
113-day-old rat hearts (left panel). Heart failure rats are compared to Sham (right panel). The values obtained are 
normalised to six normalisation genes (Table 3) by using the method of Vandesompele (2002). The groups of 
113-day-old rats and Sham were assigned the value of 1. *p < 0.05 vs. 113-day-old rats or Sham 
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4.2.2 The expression of MHC-α and β 
To confirm the foetal, neonatal, adult and CHF cardiac phenotype, MHC-α (α type myosin 
heavy chain) and MHC-β (β type myosin heavy chain) were analysed.  
 
MHC-α (major isoform in adult heart) mRNA expression was higher in the neonatal and adult 
hearts compared to the foetal hearts analysed. The significant increase in MHC-α from the 
foetal expression level was associated with time of birth. MHC-α was decreased in CHF to 
25% of the Sham level. This is a level comparable to the foetal ones. 
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Figure 11: mRNA expression of MHC-α in foetal, neonatal, adult and failing rat hearts quantified by the 
use of real-time quantitative RT-PCR. The foetal and neonatal groups (-3 days to 5 days) are compared to the 
113-day-old rat hearts (left panel). Heart failure rats are compared to Sham (right panel). The values obtained are 
normalised to six normalisation genes (Table 3) by using the method of Vandesompele (2002). The groups of 
113-day-old rats and Sham were assigned the value of 1. *p < 0.05 vs. 113-day-old rats or Sham 
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MHC-β (minor MHC isoform in adult heart) mRNA expression was higher in the foetal and 
neonatal hearts compared to the adult hearts analysed. A significant increase in MHC-β 
expression level was associated with time of birth. The MHC-β was significantly increased in 
CHF by a doubling of the expression level compared to Sham. 
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Figure 12: mRNA expression of MHC-β in foetal, neonatal, adult and failing rat hearts quantified by the 
use of real-time quantitative RT-PCR.  The foetal and neonatal groups (-3 days to 5 days) are compared to the 
113-day-old rat hearts (left panel). Heart failure rats are compared to Sham (right panel). The values obtained are 
normalised to six normalisation genes (Table 3) by using the method of Vandesompele (2002). The groups 
of 113-day-old rats and Sham were assigned the value of 1. *p < 0.05 vs. 113-day-old rats or Sham 
 
 
The expression profiles of ANP, MHC-α and MHC-β mRNA obtained are all in line with 
previous data indicating reactivation of a foetal gene program in CHF (Razeghi et al., 2001) 
(Nakao et al., 1997). 
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4.2.3 Altered expression of serotonin receptor mRNAs in foetal and neonatal 
development and in CHF 
Expression of the 5-HT4(b) receptor mRNA 
The 5-HT4(b) mRNA expression level was significantly higher in foetal and neonatal hearts 
compared to the adult heart. The expression level of 5-HT4(b) mRNA decreased with foetal 
and neonatal development from day -3 to day 5 and reached a minimum in normal adult 
hearts (113). In the failing ventricle the 5-HT4(b) receptor expression level was increased 5-
fold compared to Sham. 
 
Although the increased expression level of 5-HT4(b) receptor mRNA in CHF was modest 
compared to that observed in foetal cardiac ventricle, it was comparable to the neonatal 
expression level. 
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Figure 13: mRNA expression of 5-HT4(b) in foetal, neonatal, adult and failing rat hearts quantified by the 
use of real-time quantitative RT-PCR. The foetal and neonatal groups (-3 days to 5 days) are compared to the 
113-day-old rat hearts (left panel). Heart failure rats are compared to Sham (right panel). The values obtained are 
normalised to six normalisation genes (Table 3) by using the method of Vandesompele (2002). The groups of 
113-day-old rats and Sham were assigned the value of 1. *p < 0.05 vs. 113-day-old rats or Sham 
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Expression of the 5-HT2A receptor mRNA 
The ventricular 5-HT2A mRNA expression level was almost identical in foetal and adult heart. 
Interestingly, a significant increase of the 5-HT2A receptor mRNA was seen at time of birth, 
but the expression level declined again during the neonatal period. The time of birth is related 
to an acute increase in wall stress associated with cardiac growth during the postnatal 
development. The 5-HT2A mRNA expression level remained unchanged in CHF compared to 
Sham. 
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Figure 14: mRNA expression of 5-HT2A in foetal, neonatal, adult and failing rat hearts quantified by the 
use of real-time quantitative RT-PCR.  The foetal and neonatal groups (-3 days to 5 days) are compared to the 
113-day-old rat hearts (left panel). Heart failure rats are compared to Sham (right panel). The values obtained are 
normalised to six normalisation genes (Table 3) by using the method of Vandesompele (2002). The groups of 
113-day-old rats and Sham were assigned the value of 1. *p < 0.05 vs. 113-day-old rats 
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Expression of the 5-HT2B receptor mRNA 
The ventricular 5-HT2B mRNA expression level was with the exception for time of birth, not 
changed in foetal and neonatal heart when compared to adult heart. However, at birth 
(associated with increased wall stress) the mRNA expression level was over twice as high. As 
observed for foetal an adult heart, there was no change in the 5-HT2B mRNA expression level 
in CHF compared to Sham. 
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Figure 15: mRNA expression of 5-HT2B in foetal, neonatal, adult and failing rat hearts quantified by the 
use of real-time quantitative RT-PCR. The foetal and neonatal groups (-3 days to 5 days) are compared to the 
113-day-old rat hearts (left panel). Heart failure rats are compared to Sham (right panel). The values obtained are 
normalised to six normalisation genes (Table 3) by using the method of Vandesompele (2002). The groups of 
13-day-old rats and Sham were assigned the value of 1. *p < 0.05 vs. 113-day-old rats 
 
45 
The expression of 5-HTT mRNA 
The serotonin transporter mRNA expression level was regulated neither with foetal and 
neonatal development, nor in heart failure. During development there may seem to be a higher 
expression of the transporter around birth, and also five days after birth, however, not 
significant. 
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Figure 16: mRNA expression of 5-HTT in foetal, neonatal, adult and failing rat hearts quantified by the 
use of real-time quantitative RT-PCR. The foetal and neonatal groups (-3 days to 5 days) are compared to the 
113-day-old rat hearts (left panel). Heart failure rats are compared to Sham (right panel). The values obtained are 
normalised to six normalisation genes (Table 3) by using the method of Vandesompele (2002). The groups of 
113-day-old rats and Sham were assigned the value of 1. 
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4.3 Cardiomyocytes and non-cardiomyocytes from aorta-banded rats 
 
To compare gene expression patterns in cardiac non-myocytes (non-cardiomyocytes, NCM) 
and myocytes (cardiomyocytes, CM) of failing rat hearts, mRNA expression of five different 
receptors (5-HT2A, 5-HT2B, 5-HT4(b), β1-AR and β2-AR) and ANP was quantified by the use of 
real-time quantitative RT-PCR in the two cell fractions from aorta-banded rat hearts.  
 
Sham, hypertrophied (AB 1-3) and heart failure rats (ABHF) were included in the study. All 
the values obtained were normalised to GAPDH expression and Sham was assigned the value 
of 1 to simplify the comparison of groups.  
 
4.3.1 The expression of ANP mRNA 
The ANP mRNA expression level was quantified to confirm the pathological phenotype of 
the heart groups analysed.   
 
Both in the NCM and CM of CHF rats, the ANP expression was highly increased. In the 
NCM the expression was elevated about 30-fold, and in the CM about 50-fold. There was also 
a significant increase in the hypertrophied rats for both cell types. 
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Figure 17: Expression of ANP mRNA in non-cardiomyocytes and cardiomyocytes of Sham, AB 1-3, and 
ABHF rats. mRNA was quantified by real-time quantitative RT-PCR and normalised to GAPDH. The left panel 
shows mRNA expression in NCM of Sham, AB 1-3 and ABHF rats, the right panel shows the expression in the 
CM. Sham was assigned the value of 1 and n=12 for all groups. * p < 0.05 
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4.3.2 Expression of the 5-HT4(b) receptor mRNA 
For 5-HT4(b) there was an increase from the Sham through the AB 1-3 group and to the failing 
heart. The level was elevated 6-fold in both the NCM and CM of ABHF rats. 
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Figure 18: Expression of 5-HT4(b) mRNA in non-cardiomyocytes and cardiomyocytes of Sham, AB 1-3 and 
ABHF rats. mRNA was quantified by real-time quantitative RT-PCR and normalised to GAPDH. The left panel 
shows mRNA expression in NCM of Sham, AB 1-3 and ABHF rats, the right panel shows the expression in the 
CM. Sham was assigned the value of 1 and n=12 for all groups. * p < 0.05 vs. Sham  
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4.3.3 Expression of the 5-HT2A receptor mRNA 
The mRNA expression of the 5-HT2A receptor was increased in hypertrophied and heart 
failure rats, both in NCM and CM. In the NCM the amount of mRNA was unsignificantly 
doubled, compared to Sham, both in the AB 1-3 and ABHF group. For the CM the expression 
was significantly elevated 3-fold both in the AB 1-3 and ABHF group compared to Sham. 
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Figure 19: Expression of 5-HT2A mRNA in non-cardiomyocytes and cardiomyocytes of Sham, AB 1-3 and 
ABHF rats. mRNA was quantified by real-time quantitative RT-PCR and normalised to GAPDH. The left panel 
shows mRNA expression in NCM of Sham, AB 1-3 and ABHF rats, the right panel shows the expression in the 
CM. Sham was assigned the value of 1 and n=12 for all groups. * p < 0.05 vs. Sham 
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4.3.4 Expression of the 5-HT2B receptor mRNA 
In the CHF group of the NCM, expression of the 5-HT2B receptor was significantly elevated 
4-fold, compared to both Sham and the AB 1-3 group. Concerning the CM, the level 
decreased by 50% going from Sham to AB 1-3 and ABHF rats, but this was not a significant 
decrease. 
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Figure 20: Expression of 5-HT2B mRNA in non-cardiomyocytes and cardiomyocytes of Sham, AB 1-3 and 
ABHF rats. mRNA was quantified by real-time quantitative RT-PCR and normalised to GAPDH. The left panel 
shows mRNA expression in NCM of Sham, AB 1-3 and ABHF rats, the right panel shows the expression in the 
CM. Sham was assigned the value of 1 and n=12 for all groups. * p < 0.05 vs. Sham 
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4.3.5 Expression of the β1-AR mRNA 
Among the β-adrenergic receptors the β1-AR is the most abundant one in mammalian heart 
and compromises about 70-80% of the total β-AR number. Both β1- and β2-ARs mediate 
positive inotropic response in heart, both in human and rat. 
 
The β1-AR mRNA expression was decreased in the hypertrophied hearts and the failing ones, 
both in the NCM and the CM, however, not significantly. 
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Figure 21: Expression of β1-AR mRNA in non-cardiomyocytes and cardiomyocytes of Sham, AB 1-3 and 
ABHF rats. mRNA was quantified by real-time quantitative RT-PCR and normalised to GAPDH. The left panel 
shows mRNA expression in NCM of Sham, AB 1-3 and ABHF rats, the right panel shows the expression in the 
CM. Sham was assigned the value of 1 and n=12 for all groups. 
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4.3.6 Expression of the β2-AR mRNA 
The β2-ARs mediate positive inotropic response in heart. The receptors are primarily 
expressed in cells other than cardiac myocytes (e.g. endothelial cells, fibroblasts and vascular 
smooth muscle cells). However, they can mediate functional responses in cardiomyocytes. 
The receptors are responsible for causing smooth muscle relaxation in many organs, e.g. the 
bronchi. 
 
For the β2-AR a significant increase in mRNA expression was detected in the NCM of the 
ABHF group. The expression was twice as high in this group, compared to Sham and 
hypertrophied hearts. In the CM the mRNA expression was equal in all three groups (Sham, 
AB 1-3 and ABHF). 
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Figure 22: Expression of β2-AR mRNA in non-cardiomyocytes and cardiomyocytes of Sham, AB 1-3 and 
ABHF rats. mRNA was quantified by real-time quantitative RT-PCR and normalised to GAPDH. The left panel 
shows mRNA expression in NCM of Sham, AB 1-3 and ABHF rats, the right panel shows the expression in the 
CM. Sham was assigned the value of 1 and n=12 for all groups. * p < 0.05 vs. Sham 
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5. DISCUSSION 
 
Before developing drugs it is necessary to fully understand the pathophysiology of heart 
failure as well as the underlying mechanisms. Increased interest is turned to find the genetic 
factors involved in heart failure. A hallmark in CHF is changes in the myocardial phenotype 
due to a reintroduction of a foetal gene program, with a pattern of gene expression different 
from that in adult myocardium. The profile of gene expression in the foetal and failing heart, 
however, is largely unknown. 
 
 
5.1 Experimental considerations 
 
In this study real-time quantitative RT-PCR was used to determine the mRNA level of 
different genes concerning the serotonergic system in left ventricle from foetal, neonatal and 
congestive heart failure rats. mRNA from cardiomyocytes and non-cardiomyocytes of heart 
failure rats were also included in the study. All values were normalised and compared to 
Sham operated and/or adult rats. 
 
Real-time quantitative RT-PCR is no longer limited to specialist core facilities. It has become 
an established and common technique for quantifying mRNA in biological samples. Benefits 
of this procedure over conventional methods for measuring RNA include its sensitivity, large 
dynamic range, and the potential for high throughput as well as accurate quantification 
(Huggett et al., 2005). 
 
The method is based on the assumption that there is a quantitative relationship between 
amount of starting target sequence and amount of PCR product at any given cycle. Since the 
quantitation relies on Ct values determined during the detectable exponential phase of the 
polymerase chain reaction, the effect of limiting reagents will not affect the results and the 
quantification is therefore more precise and reproducible than in regular PCR (Bustin, 2000). 
The variability of the data obtained from real-time quantitative RT-PCR reactions is also 
significantly lower than for regular PCR (Bustin, 2000). 
 
Although real-time quantitative RT-PCR is widely used to quantify biologically relevant 
changes in mRNA levels, there remain a number of problems associated with its use. To 
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achieve quantitative benefit from the method, it is important to make use of the correct 
normalisation strategy. This is to control for experimental error introduced during the 
multistage process required to extract and process the RNA (Huggett et al., 2005). Several 
strategies have been proposed for normalising real-time RT-PCR data. These range from 
ensuring that similar samples sizes are chosen to using an internal housekeeping or reference 
gene. By using mRNA of reference genes you have a strategy that is simple to use, and you 
also have an internal control that is subjected to the same conditions as the mRNA of interest, 
also measured by real-time quantitative RT-PCR (Huggett et al., 2005). 
 
GAPDH has been used as a normalisation gene in wide-ranging studies and its expression is 
claimed to be stable over time and not to be affected by experimental factors (Winer et al., 
1999). However, GAPDH may not be as stable as first anticipated and its expression level 
seems to vary between different individuals, during the cell cycle and with developmental 
stage (Bustin, 2000). The latter point is of significant importance in this study analysing 
developing foetal and neonatal hearts in addition to failing ones; a pathophysiological 
condition associated with altered gene expression. 
 
In the analysis of the foetal genes an Excel-based program was used to allow normalisation 
against multiple reference genes. geNorm allows selection of the most stable reference genes 
by use of geometric means of the expression of the candidate cDNA (Vandesompele et al., 
2002). This is a robust method for providing accurate normalisation and is consequently 
favourable if fine measurements are to be made. However, it is not always possible to 
measure multiple reference genes due to limited sample availability and cost (Huggett et al., 
2005). 
 
According to Brattelid et al. (2005b) the chosen normalisation genes, additionally to GAPDH, 
used in the foetal gene program study are fairly stable ones and allow accurate estimation of 
the gene regulation. 
 
Unlike DNA, which is as tough as old boots, RNA is extremely delicate once removed from 
its cellular environment. Its purification is much trickier than of DNA, and a template suitable 
for inclusion in an RT-PCR assay must be of highest quality if quantitative results are to be 
relevant (Bustin and Nolan, 2004). The assessment of RNA integrity by inspection of the 28S 
and 18S rRNA bands was accomplished by the use of both ordinary agarose gel 
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electrophoresis before DNase treatment, and capillary gel electrophoresis by the Agilent 2100 
Bioanalyzer after DNase treatment.  
 
Sample purity, and concentration as well, were also assessed spectrophotometrically by the 
Ultrospec 2100 Pro Spectrophotometer before DNase-treatment and by NanoDrop ND-1000 
Spectrophotometer after DNase-treatment. Samples included in the study were mainly 
selected by the quality assessment by the NanoDrop and Bioanalyzer.   
       
     
 
Figure 23: Agarose gel electrophoresis of a representative selection of samples.  
 
 
 
Figure 24: Representative example of Bioanalyzer results. The line in front (green) represents the marker. 
The next bands represent the 18S rRNA subunit and the 28S rRNA subunit, respectively.  
 
 
28S rRNA 
 
18S rRNA 
 
28S rRNA 
 
18S rRNA 
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Figure 25: Examples of Bioanalyzer results showing electropherograms (chromatograms) of two 
representative samples included further in the study.  The peak in front represents the marker. The next two 
peaks represent the 18S rRNA subunit and the 28S rRNA subunit, respectively. 
 
 
5.2 The 5-HT4(b) receptor 
 
This study demonstrates for the first time expression of the 5-HT4(b) receptor in the foetal and 
neonatal heart at levels significantly above what is observed in adult heart. The relatively high 
5-HT4(b) receptor expression in foetal heart, declining with development to a minimum in 
adult heart, suggests a role of this receptor in cardiac development. The role of the receptor in 
the developing heart remains unknown, but preliminary data in our lab indicates that the foetal 
and neonatal 5-HT4(b) receptor mediates a positive inotropic effect. In the failing heart the 5-
HT4(b) receptor mRNA expression was increased to levels comparable to foetal and neonatal 
expression. An increase in 5-HT4(b) receptor mRNA in CHF is in line with previous data from 
our group, in two different animal models of heart failure.  Both myocardial infarction and 
aortic banding-induced heart failure models show increased 5-HT4(b) receptor mRNA levels in 
failing heart (Qvigstad et al., 2005a) (Brattelid et al., 2005a). A hallmark of heart failure is the 
transition in gene expression towards a foetal genotype correlated with loss of cardiac 
functions (Francis and Tang, 2003). Although the expression is not as high as in the foetal 
hearts, the level is comparable to the neonatal expression level. This suggests that the 5-HT4(b) 
receptor may be part of a foetal gene program reactivated in heart failure.  
 
Upregulation of 5-HT4(b) mRNA levels occurred in both CM and NCM fractions similar to the 
changes observed in LV tissue (Brattelid et al., 2005a). The CM localised increase in 5-HT4(b) 
expression can explain the increase in 5-HT4(b)-mediated inotropic response to serotonin in the 
failing heart (Brattelid et al., 2004b) (Brattelid et al., 2005a) (Qvigstad et al., 2005a). Due to 
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the low level of 5-HT4(b) receptors in heart, and ventricle in particular, it is difficult to 
determine the 5-HT4(b) receptor level in ventricle by use of radioligands as well as antibodies. 
The increase in CM 5-HT4(b) expression level advocates that the 5-HT inotropic response in 
failing hearts is mediated by the 5-HT4(b) receptor. The possible role of 5-HT4(b) receptors in 
NCM is unknown. The presence of up to 14 % of CM in the NCM fraction might have 
introduced an artificial level of the 5-HT4 gene expression as observed in the NMC fraction. 
Suggesting that the 5-HT4 is expressed in the CM fraction only, entails that the 5-HT4 
expression level is underestimated in the CM fraction, due to the apparently high level of 
NCMs in the CM fraction. Although speculative, polynucleation of cardiomyocytes might 
increase the “genetic power” of the cardiomyocytes compared to the non-cardiomyocytes. 
 
 
5.3 The 5-HT2A receptor 
 
The almost identical 5-HT2A mRNA expression level in foetal, adult, Sham operated and CHF 
rats suggests a minor role of this receptor in chronic heart failure. However, the significant 
increase in 5-HT2A observed at the time of birth might imply an important role of 5-HT2A 
receptor in acute heart failure.  
 
In acute CHF (dominated by the onset of hypertrophy) the 5-HT2A mRNA expression and 
function is significantly increased (Qvigstad et al., 2005b). Likewise, the 5-HT2A receptor is 
increased significantly at both the functional and mRNA level in hypertrophic hearts in a rat 
aortic banding model (Brattelid et al., 2005a). Both acute CHF and aortic banding is 
associated with an increase in wall stress. The wall stress is also increased at the time of birth 
as a result of significant rearrangement of the cardiac circulation due to onset of lung 
respiration and closure of foramen ovale. For this reason neonatal hearts of newborns are also 
exposed to an acute increase in wall stress associated with cardiac growth during the 
development of the heart. The increased 5-HT2A receptor mRNA expression level is therefore 
possibly induced by the acute increase in wall stress at the time of birth. The acute increase in 
5-HT2A receptor mRNA does not seem to last, and the 5-HT2A expression level is gradually 
decreased again back to a foetal and adult level in the early neonatal development. 
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In hypertrophic and failing hearts of aorta-banded rats both the CM and NCM fractions 
displayed a significant increase in 5-HT2A receptor mRNA level. The aorta-banded rats are 
exposed to an increased left ventricular wall stress. This is in line with earlier findings 
indicating a role of the 5-HT2A receptor in acute and longstanding hypertrophic heart failure 
(Qvigstad et al., 2005b) (Brattelid et al., 2005a). 
 
The increase in mRNA level of the 5-HT2A receptor at birth and in the hypertrophic heart 
could reflect a role of this receptor in the response to the increased wall stress. 
 
 
5.4 The 5-HT2B receptor 
 
The coincidence of increased 5-HT2B mRNA and increased wall stress at birth supports 
previous studies in transgenic (Nebigil et al., 2003) and knockout (Nebigil et al., 2000) 
(Nebigil et al., 2001) mouse models. Nebigil et al. (2000) provided genetic evidence that 5-
HT via 5-HT2B receptor regulates differentiation and proliferation of developing and adult 
heart. Knocking out the 5-HT2B gene leads to embryonic and neonatal death caused by heart 
defects. Nebigil et al. (2001) further showed that ablation of the 5-HT2B receptor leads to 
dilated cardiomyopathy and provides strong genetic evidence that serotonin via the 5-HT2B 
receptor regulates cardiac structure and function. On the other hand, overexpression of 5-
HT2B receptor in heart leads to compensated hypertrophic cardiomyopathy accompanied by 
abnormal mitochondrial proliferation and enzyme activity. These mice have hypertrophy as a 
result of increased number of cardiomyocytes and increased growth (Nebigil et al., 2003). The 
acute increase in wall stress at birth and increased 5-HT2B receptor mRNA level is consistent 
with a role of the 5-HT2B receptor in cardiac hypertrophy. However, in the hypertrophic hearts 
analysed, the 5-HT2B receptor increased 4-fold in the failing NCM fraction, suggesting a role 
of this receptor mainly in the non-contractile tissue. It has recently been demonstrated that the 
5-HT2B receptor induces hypertrophy by control of cytokine production in ventricular 
fibroblasts (Jaffre et al., 2004). This suggests a role of the 5-HT2B receptor in hypertrophy-
induced heart failure, consistent with induction of mRNA expression of this receptor 
primarily in fibroblasts. 
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5.5 The serotonin transporter 
 
The serotonin transporter expression level is regulated neither throughout foetal and neonatal 
development, nor in heart failure. SERT was analysed because it is the key mechanism 
controlling serotonin concentration in major heart diseases. A regulation of the SERT in 
cardiac tissue could have been an indication of local regulation of the 5-HT level with 
functional implications on the 5-HT4-mediated inotropic effect.  The importance of SERT in 
heart development has been demonstrated in SERT knock out mice where the left ventricle 
decreased compared to normal mice (Eddahibi et al., 2000). The reduced heart size of the 
SERT knock out mice did not affect the hemodynamic parameters analysed and is therefore 
probably not a master key in heart development. Although the SERT is not regulated in the 
developing heart and heart failure, Sari and Zhou (2003) demonstrated that SERT is important 
for regulation of the 5-HT level in the development of foetal heart cells and its implication in 
the cell proliferation. 
 
 
5.6 The β-adrenergic receptors 
 
The β1-adrenergic receptor mRNA expression was not regulated in either the hypertrophied or 
the failing heart NCM and CM fractions, whereas the β2-adrenergic receptor mRNA 
expression increased in the failing NCM fraction only. In human heart failure there is a loss of 
responsiveness (desensitisation) to β-AR stimulation by catecholamines associated with a 
decrease in the receptor density (Brodde and Michel, 1999). The lack of a significant down 
regulation of β1-AR mRNA in heart failure is at variance with some previous reports (Böhm 
et al., 1990) (Brodde and Michel, 1999) (Brodde et al., 2001) but supported at the receptor 
level by Sjaastad et al. (2003) who did not find any differences of total β-AR binding between 
CHF and Sham in a myocardial infarction rat model. Gu et al. (1998) demonstrated regional 
differences in the β-AR expression in the failing heart at the protein level with a significant 
down regulation of the receptors in the infarction area and the border zone and no change in 
the viable area of the failing heart compared to Sham. The gene expression of the failing heart 
might therefore be affected by the etiology leading to heart failure. A direct comparison of the 
results obtained here in the aorta-banded heart failure model might differ with the myocardial 
infarction induced heart failure. 
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The 2-fold increase in β2-AR mRNA expression in NCM of ABHF is difficult to explain. The 
anticipated inotropic role of β2-AR in heart suggests that expression of the receptor should at 
least occur in the CM. However, the β2-AR mRNA expression levels were not changed in 
hypertrophic and failing heart, and the increase of this receptor in NCM can therefore not be 
explained by contamination of CM in the NCM fraction. The NCM β2-AR expression needs 
further investigations. 
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6. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
♥ The high 5-HT4(b) mRNA expression in CHF, foetal and neonatal cardiac ventricle is 
consistent with 5-HT4(b) receptor as a representative of the foetal gene program 
reactivated in CHF. 
♥ The foetal expression of 5-HT4(b) receptor mRNA is consistent with a possible role for 
the 5-HT4 receptor in cardiac development. 
♥ The increase in 5-HT2A receptor mRNA is associated with birth, consistent with a 
possible role of 5-HT2A receptor in the hypertrophic response. 
♥ The transitory increase in the 5-HT2B receptor mRNA at birth might be involved in the 
hypertrophic response of the acutely stretched heart. 
♥ The serotonin transporter is not regulated throughout foetal and neonatal development 
or in heart failure. 
♥ 5-HT2A and 5-HT4(b) receptors are induced in cardiomyocytes in myocardial 
hypertrophy and CHF after banding of the ascending aorta.  
♥ Increased 5-HT2B mRNA expression in hypertrophic and failing ventricles occurs 
primarily in the non-cardiomyocyte cell population.  
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8. APPENDIX 
 
8.1 Materials and recipes 
8.1.1 Chemicals and reagents 
 
Chemical/Reagent Abbreviation Manufacturer Cat. No. 
2X Master Mix  Eurogentec RT-QP2X-03-50+ 
Absolute (100%) ethanol  Arcus - 
Ammonium acetate, 5M  Ambion 9071 
Chloroform  SDS C-2432 
dNTP Mix, 10mM**  Invitrogen 18427-013 
Ethanol (96%)  Arcus - 
Ethidium bromide EtBr Sigma E8751 
Formamide  Sigma F7508 
Glycoblue  Ambion 9515 
Isopropanol  Arcus 1-9516 
Loading buffer**  - - 
Oligo (dT)12-18  Invitrogen - 
Primers  Invitrogen - 
Primers and Probe mixes   Applied Biosystems - 
Probes  Eurogentec - 
RNA 6000 Ladder  Ambion 7152 
RNAlater  Ambion 7021 
Nuclease-free water (not DEPC treated)  Ambion 9932 
RNA 6000 Nano LabChip kit*  Agilent Technologies 5065-4476 
RNaseOut Recombinant Ribonuclease  
Inhibitor, 40U/µl 
 Invitrogen 10777-019 
RNaseZAP  Ambion 9780 
RQ1 RNase-free DNase (1U/µl)*  Promega E3730 
SeaKem LE Agarose  Cambrex 50004 
SuperScript III RNase H-Reverse 
Transcriptase, 200U/µl* 
 Invitrogen 18080-044 
TAE buffer**  - - 
Trizol  Invitrogen 15596-018 
*Content of commercial kits is specified in 8.1.2 **Content of reagents is specified in 8.1.3 
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8.1.2 Content of commercial kits 
 
• RQ1 RNase-free DNase 
o RQ1 RNase-free DNase 10X Reaction Buffer (400mM Tris-HCl (pH 8.0 at 
25ºC), 100mM MgSO4, 10 mM CaCl2) 
o RQ1 RNase-free DNase (1U/µl) 
o RQ1 DNase Stop Solution (20mM EGT at 25ºC) 
 
• RNA 6000 Nano LabChip kit  
RNA 6000 Nano Chips 
o Nano Chips 
o Electrode Cleaners 
RNA 6000 Nano Reagents & Supplies (reorder number 5065-4475, Agilent Technologies) 
o RNA Nano Dye Concentrate 
o RNA 6000 Nano Marker 
o RNA 6000 Nano Gel Matrix 
o Spin filters 
Tubes for Gel-Dye Mix 
o Safe-Lock Eppendorf Tubes PCR Clean (DNase-/RNase- free) 
 
• SuperScript III RNase H-Reverse Transcriptase 
o SuperScript III RT, 200 U/µl 
o 5X First-Strand Buffer (250 mM Tris-HCl (pH 8.3 at room temperature), 375 
mM KCl, 15 mM MgCl2) 
o 0.1 M DTT 
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8.1.3 Content of reagents 
 
Reagent Ingredients 
dNTP Mix, 10mM Same amount dATP, dGTP,  dCTP and dTTP  
Loading buffer 1 mM EDTA 
0.25% bromophenol blue 
0.25% xylene cyanol FF 
50% glycerol 
Stored at 4ºC 
TAE buffer 0.04 M Tris-acetate 
1 mM EDTA 
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8.2 Protocols 
8.2.1 Homogenisation, phase separation, RNA precipitation and washing 
1. Wash 100 mg of tissue in NaCl and tear it apart into small pieces. Homogenise in 
1.5ml of Trizol together with a ceramic particle by using a shaker machine (Retsch 
MM301). Use 2ml tubes. 
2. Remove insoluble material from the homogenates by centrifugation at 12000 x g for 
10 minutes at 2-8ºC by the use of Biofuge fresco (Heraeus). 
3. Incubate the homogenates for 5 minutes at 15-30ºC (room temperature). 
4. Spin the Phase Lock Gel tubes for about 30 seconds to collect the Phase Lock Gel to 
pellet. 
5. Transfer the clear supernatant from the homogenates to the Phase Lock Gel tubes. 
6. Add 200 µl of chloroform per 1 ml of Trizol and shake vigorously by hand for 15 
seconds. 
7. Incubate for 2-3 minutes at 15-30ºC. 
8. Centrifuge the samples at 12000 x g for 15 minutes at 2-8ºC. 
9. Transfer the colourless upper aqueous phase to fresh tubes. 
10. Precipitate the RNA by mixing with 500µl isopropanol per 1ml of Trizol.  
11. Incubate samples at 15-30ºC for 10 minutes. 
12. Centrifuge at 12000 x g for 10 minutes at 2-8ºC. 
13. Remove the supernatant and wash the RNA pellet once with 1ml 75% ethanol per 1ml 
of Trizol. 
14. Mix the sample by vortexing and centrifuge at 7500 x g for 5 minutes at 2-8ºC. 
15. Remove the ethanol and let the pellets air-dry for 5-10 minutes.  
16. Dissolve RNA in RNase-free water by passing the solution a few times through a 
pipette tip. 
17. Incubate on a heating block (BLOCKHEATER, Stuart Scientific) for 10 minutes at 
55-60ºC to dissolve the RNA completely.  
18. Pipette aliquots for spectrophotometric determination and agarose gel electrophoresis.  
19. Add 1µl of RNaseOut per 20µl sample volume and mix by using the pipette.  
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8.2.2 Spectrophotometric determination of RNA purity and concentration by the use of 
Ultrospec 2100 pro 
1. Mix 5µl RNA solution (before adding RNaseOut in step 19 in protocol description 
8.2.1!) with 95µl RNase-free water.  
2. Calibrate the UV-detector by using 100µl of RNase-free water. 
3. Pipette 100µl diluted sample into the cuvette. 
4. Make the measurements. 
 
8.2.3 Agarose gel electrophoresis 
1. Mix 5µl of the sample (before adding the RNaseOut in step 18 in protocol description 
8.2.1!) with 2µl formamide.  
2. Mix 0.8g agarose (SeaKem LE Agarose, Cambrex) with 50ml 1X TAE buffer (or 1.3g 
agarose in 100ml buffer for a bigger gel run) and bring it to the boiling point several 
times until dissolved by the use of a microwave oven. Mix thoroughly after each 
parboiling.  
3. Add 7µl of ethidium bromide (or 14µl for a bigger gel). Mix thoroughly. 
4. Cast the gel in a horizontal tray. 
5. Heat the samples at 70ºC for 5-10 minutes. 
6. Cool on wet ice for a couple of minutes. 
7. Add 2µl of loading buffer to each sample and spin down. 
8. Load the samples on to the gel. 
9. Use a voltage of 50V and let the samples run for about 45 minutes. Make sure that the 
poles are right.  
10. Picture the gel by the use of UV light (Epi Chemi II Darkroom, UVP). 
 
8.2.4 DNase treatment of RNA  
1. Set up the DNase-reaction as follows: 
RNA in RNase-free water     25µg 
RQ1 RNase-free DNase 10X Reaction Buffer (See note 1) 5µl 
RQ1 RNase-free DNase (1U/µl) (See note 2)  5µl 
RNase-free water to a final volume of   50µl  
 
Notes: 
1) 1µl reaction buffer per 10µl total sample volume. 
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2) 1µl DNase (1U/µl) per 5µg DNA. 
2. Incubate at 37ºC for 30 minutes by the use of a heater (Termaks, KEBOLab). 
3. Add 1µl of DNase Stop Solution per 10µl total sample volume to terminate the 
reaction. 
4. Incubate at 65ºC for 10 minutes to inactivate the DNase. 
 
8.2.5 Precipitation of RNA after DNase treatment 
1. Add the following components to the DNase treated RNA samples: 
0.1 volume 5M ammonium acetate  
1µl Glycoblue 
2.5 volumes absolute (100%) ethanol 
2. Mix thoroughly by vortexing. 
3. Incubate at -20ºC over night or at -70ºC for 30 minutes. 
4. Recover the RNA by centrifugation at 12000 x g for 30 minutes at 4ºC. 
5. Remove the supernatant carefully using a pipette. 
6. Centrifuge the tubes briefly one more time and remove the remaining fluid.  
7. Add 1ml of 75% ethanol to wash the pellets. Shake carefully. 
8. Centrifuge at 12000 x g for 10 minutes at 4ºC. 
9. Remove the supernatant as in steps 5 and 6. 
10. Dry the pellets for a few minutes. 
11. Add 20µl of RNase-free water to dissolve the RNA. 
12. Pipette aliquots for spectrophotometric determination by the use of NanoDrop. 
13. Add 1µl RNaseOut per 20µl sample volume to the remaining RNA solutions. Mix by 
using the pipette tip. 
14. Freeze at -70ºC. 
 
8.2.6 Determination of RNA purity and concentration by the use of NanoDrop ND-1000 
Spectrophotometer 
1. Mix 2µl RNA solution (before adding the RNaseOut!) with 8µl RNase-free water. 
2. Run a blank by the use of 2µl RNase-free water.  
3. Use volumes of 2µl and run each sample twice. 
 
  72 
8.2.7 The Agilent 2100 Bioanalyzer; Determination of RNA quality  
 
Allow all reagents to equilibrate to room temperature for 30 minutes before use! Wear 
gloves. 
 
Decontaminating the electrodes 
1. Slowly fill one of the wells of an electrode cleaner with 350µl RNaseZAP (Ambion). 
2. Place the electrode cleaner in the Bioanalyzer, close the lid and leave it there for about 
1 minute. 
3. Slowly fill one of the wells of another electrode cleaner with 350µl RNase-free water. 
4. Place the electrode cleaner in the Bioanalyzer and leave it there for about 10 seconds. 
Open the lid, remove the electrode cleaner and wait another 10 seconds before you 
close the lid again. (Save the electrode cleaner for cleaning after the run.) 
 
Preparing the gel 
1. Place 550µl of RNA 6000 Nano gel matrix (Agilent Technologies) (red) into the top 
receptacle of a spin filter and spin for 10 minutes at 1500 x g ± 20% (corresponding 
4000rpm). 
2. Discard the filter and aliquot 65µl filtered gel into 0.5ml microcentrifuge tubes (Safe-
Lock Eppendorf Tubes PCR Clean (DNase-/RNase-free), Agilent Technologies). Use 
the aliquots within one month of preparation. 
 
Preparing the gel-dye mix 
1. Vortex RNA 6000 Nano dye concentrate (Agilent Technologies) (blue) for 10 seconds 
and spin down. 
2. Add 1µl of dye to a 65µl aliquot of filtered gel. 
3. Vortex and visually inspect proper mixing of gel and dye. 
4. Spin tube for 10 minutes at room temperature at 13000 x g (14000 rpm). Use prepared 
gel-dye mix within one day. 
 
Loading the gel-dye mix  
1. Take a new RNA Nano Chip (Agilent Technologies) out of its sealed bag and place it 
on the Chip Priming Station (Agilent Technologies). 
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2. Pipette 9.0µl of the gel-dye mix into the well marked G. Insert the tip of the pipette to 
the bottom of the chip well when dispensing! 
 
 
 
      
 
      Figure 26: How to hold the pipette tip. It is very important to hold the pipette tip as shown to the left  
      to avoid bubbles in the wells. 
  
 
3. Set the timer to 30 seconds. Make sure that the plunger is at 1ml and then close the 
Chip Priming Station. 
4. Press the plunger until it is held by the syringe clip and wait for exactly 30 seconds 
and then release the plunger with the clip release mechanism. Wait for 5 seconds and 
then slowly pull back the plunger to the 1ml position. Open the Chip Priming Station. 
5. Pipette 9.0µl of the gel-dye mix in each of the wells marked G. Discard the remaining 
gel-dye mix. 
 
Loading the RNA Nano Marker 
1. Pipette 5µl of the RNA 6000 Nano Marker (green) into the well marked with ladder 
symbol and each of the 12 sample wells. Do not leave any wells empty! Add 6µl 
(instead of 5µl) of the RNA 6000 Nano Marker to each unused sample well. 
 
Loading the ladder and samples 
1. Aliquot the amount of RNA 6000 ladder that you will use within a day into a RNase-
free microcentrifuge tube and heat denature it for 2 minutes at 70ºC before use. 
2. Pipette 1µl of the ladder into the well marked with the ladder symbol. 
3. To minimise the secondary structure, heat denature (70ºC for 2 minutes) the samples 
before loading on the chip. 
4. Pipette 1µl of each sample into each of the 12 sample wells. 
5. Place the chip in the adapter of the vortex mixer. Vortex for 1 minute at the IKA 
Vortexer Mixer (Agilent Technologies; set-point 2400rpm). 
6. Start the Agilent 2100 Bioanalyzer run within 5 minutes. 
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The run (www.agilent.com/chem/labonachip) 
1. The samples move through the microchannels from the sample wells. 
2. The samples are injected into the separation channel. 
3. RNA fragments are separated according to their size by means of molecular sieving. 
4. RNA fragments are detected by fluorescence at the detection point and results are 
recorded and analyzed with the Agilent 2100 Bioanalyzer software.  
5. Once detected the samples pass into the waste/buffer well. 
 
Cleaning up after the RNA Nano Chip Run 
1. When the run is finished, remove the RNA Nano Chip from the Bioanalyzer 
immediately.  
2. Place the electrode cleaner with RNase-free water in the Bioanalyzer and leave it there 
for about 10 seconds. Open the lid, remove the electrode cleaner and wait another 10 
seconds before closing the lid again. 
 
For further details see Agilent Technologies (2003). 
 
8.2.8 First strand cDNA synthesis 
1. Add the following components to nuclease-free microcentrifuge tubes: 
Oligo (dT)12-18        2 µl 
dNTP Mix, 10mM (same amount dATP, dGTP, dCTP and  
dTTP, Invitrogen)       2 µl 
Total RNA in RNase-free water     7.5 µg 
RNase- free water to a total volume of     26 µl 
2. Heat at 65ºC for 5 minutes using a heating block (PTC-100 Programmable Thermal 
Controller, MJ Research) and incubate on wet ice for a couple of minutes. 
3. Collect the contents of the tubes by using a centrifuge (Varifuge 3.0R, Heraeus 
Instruments).  
4. Add the following components: 
5X First-Strand Buffer      8 µl 
0.1 M DTT        2 µl 
RNaseOut Recombinant RNase Inhibitor (40U/µl)   2 µl 
SuperScript III RT (200 U/µl)     2 µl 
5. Mix gently by pipetting. 
Mix 2 
Mix 1 
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6. Incubate at 25ºC for 5 minutes, then at 50ºC for 60 minutes. Finally inactivate the 
reaction by heating at 70ºC for 15 minutes. Cool. All this can be done by using a PTC-
100 Programmable Thermal Controller (MJ Research). 
 
For all the samples parallel reactions should be run in the absence of reverse transcriptase. 
Replace the reverse transcriptase and the RNaseOut volume with RNase-free water. 
 
8.2.9 Design of primers and probes in Primer Express 
Guidelines for primer design 
1. The melting point of the primers should be 58-60ºC. 
2. No more than two (three) Gs and/or Cs in the last five nucleotides at the 3´end of the 
primers are accepted.  
3. Design primers as close to the probe as possible. 
 
Guidelines for probe design 
1. The melting temperature of the probe should be 68-70ºC. 
2. Select the strand that gives the probe more Cs than Gs. (The probe can be run both 
ways.) 
3. The first base at the 5´ end can not be a G. The G will then be able to function as a 
quencher.  
 
8.2.10 Real-time quantitative RT-PCR 
1. Dilute each sample of template (including the standards) with 60µl of RNase-free 
water.  
2. Make a second dilution; Pipette 3µl of the template dilution already made and mix 
with 295µl of RNase-free water. Use this second dilution when looking at highly 
expressed genes. 
 
Store the dilutions at -20ºC. 
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3. Mix the following volumes (µl) of the given components: 
RNase-free water    5.80 x (3 x number of samples + 2) 
Primer 1 (forward) (10µM)   0.66 x (3 x number of samples + 2) 
Primer 2 (reverse) (10µM)   0.66 x (3 x number of samples + 2)  
Probe TaqMan (5µM)    0.88 x (3 x number of samples + 2) 
2X Master Mix (Eurogentec)   11.0 x (3 x number of samples + 2) 
4. Pipette 57µl of this reaction mix and add 9µl of template dilution. Use 0.2ml RNase-
free microcentrifuge tubes (Sarstedt). This volume of 66µl is now a triplicate master. 
Keep on ice while working. 
5. Use 384-well PCR plates and pipette 3 x 20µl from each triplicate master. 
6. Cover the PCR plate with optically clear ceiling tape (Sarstedt) and centrifuge by 
using a Varifuge 3.0R to collect the samples and remove air bubbles. 
7. Run real-time quantitative PCR (ABI Prism 7900HT Sequence Detection System). 
Run 40 cycles, or 50 when looking at smaller amounts of mRNA. The run takes about 
2 hours (or more when 50 cycles).  
 
 
 
